GENELUX CORPORATION Share-based Payment Arrangement, Expense
GENELUX CORPORATION (GNLX) reported Share-based Payment Arrangement, Expense of $2.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-13
- GENELUX CORPORATION share-based payment arrangement, expense for the quarter ending 2026-06-30 was $2.27M, a 53.37% increase year-over-year.
- GENELUX CORPORATION share-based payment arrangement, expense for the quarter ending 2026-03-31 was $1.78M, a 16.25% increase year-over-year.
- GENELUX CORPORATION share-based payment arrangement, expense for the quarter ending 2025-12-31 was $1.92M, a 9.59% decline year-over-year.
- GENELUX CORPORATION share-based payment arrangement, expense for the quarter ending 2025-09-30 was $2.63M, a 50.14% increase year-over-year.
- GENELUX CORPORATION share-based payment arrangement, expense for fiscal 2025 was $7.58M, a 6.63% decline from fiscal 2024.
- GENELUX CORPORATION share-based payment arrangement, expense for fiscal 2024 was $8.11M, a 222.62% increase from fiscal 2023.
- GENELUX CORPORATION share-based payment arrangement, expense for fiscal 2023 was $2.52M, a 4.14% increase from fiscal 2022.
- GENELUX CORPORATION share-based payment arrangement, expense for fiscal 2022 was $2.42M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.27M 10-Q · filed 2026-08-13 | $4.05M 10-Q · filed 2026-08-13 | $5.98M derived: sum of 3 quarters · filed 2026-08-13 | $8.61M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $1.78M 10-Q · filed 2026-05-07 | $3.71M derived: sum of 2 quarters · filed 2026-05-07 | $6.34M derived: sum of 3 quarters · filed 2026-05-07 | $7.82M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $4.56M derived: sum of 2 quarters · filed 2026-03-19 | $6.04M derived: sum of 3 quarters · filed 2026-08-13 | $7.58M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $2.63M 10-Q · filed 2025-11-05 | $4.12M derived: sum of 2 quarters · filed 2026-08-13 | $5.65M 10-Q · filed 2025-11-05 | $7.78M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $1.48M 10-Q · filed 2026-08-13 | $3.01M 10-Q · filed 2026-08-13 | $5.14M derived: sum of 3 quarters · filed 2026-08-13 | $6.90M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $1.53M 10-Q · filed 2026-05-07 | $3.66M derived: sum of 2 quarters · filed 2026-05-07 | $5.42M derived: sum of 3 quarters · filed 2026-05-07 | $6.86M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $3.88M derived: sum of 2 quarters · filed 2026-03-19 | $5.32M derived: sum of 3 quarters · filed 2026-03-19 | $8.11M 10-K · filed 2026-03-19 | $5.74M 10-K · filed 2025-03-28 | ||
| 2024-09-30 | $1.75M 10-Q · filed 2025-11-05 | $3.20M derived: sum of 2 quarters · filed 2025-11-05 | $5.99M 10-Q · filed 2025-11-05 | $4.31M 10-Q · filed 2024-11-14 | $6.22M derived: sum of 4 quarters · filed 2025-11-05 | ||
| 2024-06-30 | $1.44M 10-Q · filed 2025-08-07 | $4.23M 10-Q · filed 2025-08-07 | $2.79M 10-Q · filed 2024-08-14 | $4.46M derived: sum of 3 quarters · filed 2025-08-07 | $4.98M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $1.49M 10-Q · filed 2024-05-09 | $3.02M derived: sum of 2 quarters · filed 2025-03-28 | $3.54M derived: sum of 3 quarters · filed 2025-03-28 | $3.78M derived: sum of 4 quarters · filed 2025-03-28 | |||
| 2023-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $2.05M derived: sum of 2 quarters · filed 2025-03-28 | $2.29M derived: sum of 3 quarters · filed 2025-03-28 | $2.52M 10-K · filed 2025-03-28 | |||
| 2023-09-30 | $515.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $755.00K derived: sum of 2 quarters · filed 2024-11-14 | $982.00K 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | $240.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $467.00K 10-Q · filed 2023-08-14 | |||||
| 2023-03-31 | $227.00K 10-Q · filed 2023-05-15 | ||||||
| 2022-12-31 | $2.42M 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |